Holly Ann Baldwin is the CEO Designate for a potential spin out organisation from Oxford University. Academic teams have developed two unique digital platforms for better engagement, recruitment and consent practices in the life science and clinical trial marketplace.
Holly started her career in the medicine in the US Army and specialised in cardiac diseases and transplant. After 10+ years in patient care, academics and clinical trials, she transitioned to medical device companies (Medtronic & HeartWare). Holly spent 11 years in commercial roles within sales, clinical trials, quality, and manufacturing; including high profile projects supporting a company exit of $1B in 2016.
Holly attended Rutgers University (BSc), Seton Hall University (MSc) and Henley Business School (MBA).
Holly’s primary goal is to take the two market ready products and transform the clinical trial space with ethical digital technologies focused on data-sharing frameworks, governance and best practice. She seeks to raise £1M to spin out from Oxford University, hire talent to deliver to eagerly waiting customers.